Treatment of bone-associated cancers
View Patent ↗The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
1. A therapeutic method for treating a bone-associated cancer comprising:
(a) parenterally administering a dose of 153 Sm-EDTMP to said patient in an aqueous vehicle comprising an effective antiradiolytic amount of a pharmaceutically acceptable radioprotectant; and
(c) administering to said patient an effective amount of chemotherapeutic agent in conjunction with 153 Sm-EDTMP wherein the patient is not subjected to total body irradiation or stem cell transplantation in conjunction with the therapeutic method.
2. The method of claim 1 wherein the cancer is multiple myeloma.
3. The method of claims 1 or 2 wherein the patient is treated with chemotherapy prior to step (a).
4. The method of claims 1 or 2 wherein the patient is treated with chemotherapy after step (c).
5. The method of claim 1 wherein the radioprotectant is ascorbic acid or gentistic acid.
6. The method of claim 5 wherein the concentration of ascorbic acid is about 35-75 mg/ml.
7. The method of claim 1 wherein the vehicle is buffered to about pH 7-8.
8. The method of claim 1 where the cancer is metastatic breast or prostate cancer.
9. The method of claim 1 wherein the dose is subablative.
10. The method of claim 8 or 9 wherein the chemotherapeutic agent is a bisphosphonate.
11. The method of claim 3 wherein the chemotherapeutic agent is a bisphosphonate.
12. The method of claim 4 wherein the chemotherapeutic agent is a bisphosphonate.
13. A therapeutic method for treating a bone-associated cancer comprising:
(a) parenterally administering a dose of 153 Sm-EDTMP to said patient in an aqueous vehicle; and
(c) administering to said patient an effective amount of a bisphosphonate in conjunction with said 153 Sm-EDTMP wherein the patient is not subjected to total body irradiation or stem cell transplantation in conjunction with the therapeutic method.
14. The method of claim 13 wherein the cancer is metastatic prostate cancer or metastatic breast cancer.
15. The method of claims 13 or 14 wherein the patient is treated with the bisphosphonate prior to step (a).
16. The method of claims 13 or 14 wherein the patient is treated with the bisphosphonate after step (a).
17. The method of claims 13 or 14 wherein the bisphosphonate is pamidronate, clodronate, zoledronate, etidronate, tiludronate or alerdronate.
18. The method of claims 13 or 14 wherein the aqueous vehicle further comprises an effective antiradiolytic amount of a pharmaceutically acceptable radioprotectant.
19. The method of claim 13 wherein the vehicle is buffered to about pH 7-8.
20. The method of claim 13 or 14 wherein the dose is subablative.